Prulifloxacin

Drug Profile

Prulifloxacin

Alternative Names: AF 3012; NAD-441A; NM441; OPT-99; PrulifloxacinA brs; Pruvel; Quisnon; Sword; Sword 100; Unidrox

Latest Information Update: 19 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Shinyaku
  • Developer Angelini Group; Cubist Pharmaceuticals; Lees Pharmaceutical Holdings; Merck & Co; Nippon Shinyaku; Optimer Pharmaceuticals
  • Class Antibacterials; Dioxolanes; Fluoroquinolones; Piperazines; Quinolones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Gram-negative infections; Gram-positive infections; Pneumonia; Respiratory tract infections; Urinary tract infections
  • Phase III Acute exacerbations of chronic bronchitis; Prostatitis; Traveller's diarrhoea

Most Recent Events

  • 01 Jul 2015 Lees Pharmaceutical completes a phase III trial in Urinary tract infections in China (NCT02439632)
  • 13 May 2015 Prulifloxacin is still in phase-III development for Prostatitis, Traveller's diarrhoea and Acute exacerbations of chronic bronchitis in Italy
  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top